ClinicalTrials.gg
Active, not recruitingNCT06042153Updated Jan 13, 2026

DIALYSIS-TIR Study

A Phase 4 interventional study of Semaglutide and Placebo in Type 2 Diabetes and End Stage Renal Disease on Dialysis, sponsored by University of Texas Southwestern Medical Center. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by University of Texas Southwestern Medical Center · Phase 4, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
136th of 163
43 · median 104
Started
2023
with 19 others
Phase 4
40 of 163
17 open now
Primary completion
2027-09
later than 29 of 44 live
Registered
123rd of 163
by date

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 136th largest by enrollment, is one of 20 that started in 2023, is one of 40 in phase 4, reaches primary completion later than 29 of the 44 other live ones, and was the 123rd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will look at control of blood sugar levels in persons with type 2 diabetes mellitus currently on chronic dialysis. Researchers will compare blood sugar levels in people taking semaglutide to people taking "dummy" medicine. The treatment participants get will be decided randomly.

Participants will need to inject the study medication once a week. The study will last for 1 year and a month. Participants will be asked to wear a sensor that measures blood sugar levels for a period of 10 days at five different time points during the study.

Read the detailed description

The researchers also have a Data Safety Monitoring Plan in place.

03

Conditions studied

  • Type 2 Diabetes
  • End Stage Renal Disease on Dialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide before any trial-related activities. Trial-related activities are any procedures that are carried out as a part of trial, including activities to determine suitability for the trial.
  2. Male or female Adults (age > 18 years at the time of signing the consent)
  3. Type 2 diabetes mellitus diagnosed > 6 months prior to screening
  4. On current chronic treatment with Hemodialysis or Peritoneal dialysis for > 6 months prior to screening
  5. Current treatment with any glucose lowering pharmacotherapy, at a stable dose for at least 30 days. DPP-4 Inhibitors will be allowed at study entry and will be stopped at randomization.
  6. Minimum of 80% valid data on the 10-day Continuous Glucose Monitor download
  7. Time in Range 15 to 60%

Exclusion criteria

Exclusion Criteria:

  1. \< 23 kg/m2 at screening
  2. Current (within the past 90 days of screening) use of any GLP-1 RA
  3. Personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2
  4. Known or suspected to GLP-1 RA (trial medication(s), , or related products)
  5. Pregnant, breast-feeding or the intention of becoming pregnant, or not using effective measures
  6. Active weight loss, defined as weight loss of >5% of body weight in the past 3 months
  7. Current participation in other interventional trials or last dose of any product within 4 half- lives at the time of randomization
  8. Any medical condition which in the judgement of the investigator precludes safe participation in the trial (includes, but not limited to active neoplasm, severe heart failure, recent cardiovascular event, severe frailty, planned cardiac or vascular surgeries on the day of screening etc)
  9. If weight loss is not desired by the participant, or if the provider or investigator considers intentional weight loss to be detrimental to the health of the participant
  10. Other or secondary forms of diabetes (like type 1 diabetes, pancreatogenic diabetes mellitus, MODY, LADA, drug induced, etc.)
  11. Current diagnosis of gastroparesis or enteropathywhich in the opinion of investigator precludes safe treatment with GLP-1 RA.
  12. Hypoglycaemia unawareness, or history of frequent or severe hypoglycaemia (in the opinion of the investigator)
  13. Personal history of chronic pancreatitis, or acute pancreatitis within 180 days of screening
  14. Known current uncontrolled or unstable retinopathy (by medical history)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Arm 1 - Semaglutide

    Participants will receive semaglutide as an adjunct to standard-of-care.

    Drug: Semaglutide

  • Placebo comparator
    Arm 2- Placebo

    Participants will receive placebo (semaglutide) as an adjunct to standard-of-care.

    Drug: Placebo

Interventions

  • Semaglutide will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Subjects will start semaglutide treatment at 0.25 mg; dose will gradually be increased every 4 weeks up to 1.0 mg.

  • DrugPlacebo

    Placebo will be injected into a skin fold, in the stomach, thigh or upper arm once a week at the same day of the week (to the extent possible) throughout the trial. Participants will receive placebo at an equivalent dose to semaglutide.

06

What researchers measure

Primary outcomes

  1. Change in TIR (70-180 mg/dl)

    Measured in percentage by Continuous glucose monitor (CGM)

    Time frame: Baseline, 52 weeks

Secondary outcomes

  1. Change in Time in high range (180-250 mg/dl)

    Measured in percentage by Continuous glucose monitor (CGM)

    Time frame: Baseline, 52 weeks

  2. Change in Time in very high range (>250 mg/dl)

    Measured in percentage by Continuous glucose monitor (CGM)

    Time frame: Baseline, 52 weeks

  3. Change in Time in low range (54-69 mg/dl)

    Measured in percentage by Continuous glucose monitor (CGM)

    Time frame: Baseline, 52 weeks

  4. Change in Time in very low range (<54 mg/dl)

    Measured in percentage by Continuous glucose monitor (CGM)

    Time frame: Baseline, 52 weeks

  5. Proportion of participants with TIR 70-180 mg/dl for 70% of the day

    Measured in percentage by CGM

    Time frame: 52 weeks

  6. Proportion of participants with TIR 70-180 mg/dl with more than equal to 5% improvement from baseline

    Measured in percentage by CGM

    Time frame: 52 weeks

  7. Proportion of participants with Time below range <70 mg/dL for <4% of each day

    Measured in percentage by CGM

    Time frame: 52 weeks

  8. Proportion of participants with Time below range <54 mg/dL for <1% of each day

    Measured in percentage by CGM

    Time frame: 52 weeks

  9. Proportion of participants with Time above range >180 mg/dL for <25% of each day

    Measured in percentage by CGM

    Time frame: 52 weeks

  10. Change in haemoglobin A1c (HbA1c)

    Measured in percentage

    Time frame: Baseline, 52 weeks

  11. Total daily dose of insulin

    Measured as units/day

    Time frame: 52 weeks

  12. Number of oral glucose lowering agents

    Measured as count

    Time frame: 52 weeks

  13. Proportion of participants with >10 points improvement in % TIR 70-180 mg/dL without an increase in time below range <54 mg/dL of >0.5%

    Measured in percentage

    Time frame: 52 weeks

  14. Proportion of participants with mean glucose <154 mg/dL and <1% time below range <54 mg/dL

    Measured in percentage

    Time frame: 52 weeks

  15. Number of participants with Severe hypoglycemia

    Measured in count

    Time frame: 52 weeks

  16. Change in body weight

    Measured in kilograms

    Time frame: Baseline, 52 weeks

  17. Change in waist circumference

    Measured in centimeters

    Time frame: Baseline, 52 weeks

  18. Change in percentage total body fat

    Measured in percentage

    Time frame: Baseline, 52 weeks

  19. Change in percentage lean mass

    Measured in percentage

    Time frame: Baseline, 52 weeks

  20. Change in Inter-dialysis weight gain

    Measured in kilograms

    Time frame: Baseline, 52 weeks

  21. Number of participants hospitalized

    Measured in count

    Time frame: 52 weeks

  22. Total number of days spent in hospital

    Measured in count

    Time frame: 52 weeks

  23. Total score of Diabetes Treatment Satisfaction questionnaire

    Patient reported outcomes is assessed by Diabetes Treatment Satisfaction Score questionnaire which assesses patient satisfaction with diabetes treatment. It is composed of eight questions, each of which is scored by patients on a scale ranging from zero (e.g., "very dissatisfied", "very inconvenient") to six (e.g., "very satisfied", "very convenient"). Treatment satisfaction is assessed as the sum of the scores of the six questions on the first factor, with a higher score indicating higher treatment satisfaction.

    Time frame: 52 weeks

  24. Total score of EQ-5D-5L

    The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. Possible scores range from 0-100, where higher score indicate better outcome

    Time frame: 52 weeks

  25. Total score of Kidney disease QoL short form

    The KDQOL-SF is a self-report measure developed for individuals with kidney disease and those on dialysis. It is a shorter version of a measure developed by the same authors. It includes 43 kidney disease-targeted items, such as the effects of the disease of activities of daily living, work status, and social interaction, and 36 items that provide a measure of physical and mental health, and 1 overall health rating item ranging from 0 ("worst possible health") to 10 ("best possible health.").

    Time frame: 52 weeks

07

Study locations

5 sites
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Davita UT Southwestern - Oak Cliff
    Dallas, Texas 75224, United States
  • DaVita UT Southwestern - East Dallas
    Dallas, Texas 75228, United States
  • DaVita UT Southwestern - Preston
    Dallas, Texas 75240, United States
  • DaVita UT Southwestern - Irving
    Irving, Texas 75062, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Sep 2027, 45 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 45 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 18, 2023
StartActual
Dec 5, 2023
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06042153
Responsible party
Ildiko Lingvay (Professor, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Sep 18, 2023
Start date
Dec 5, 2023
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jan 13, 2026

Study contacts

Ildiko Lingvay, MD, MPH, MSCS
principal investigator · University of Texas Southwestern Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion